| Unique ID issued by UMIN | UMIN000055133 |
|---|---|
| Receipt number | R000062936 |
| Scientific Title | Prospective and and retrospective multicenter observational study of HER2 status just before T-DXd administration and treatment efficacy in patients with advanced gastric cancer. |
| Date of disclosure of the study information | 2024/08/02 |
| Last modified on | 2024/08/01 12:17:56 |
Prospective and and retrospective multicenter observational study of HER2 status just before T-DXd administration and treatment efficacy in patients with advanced gastric cancer.
Prospective and and retrospective multicenter observational study of HER2 status just before T-DXd administration and treatment efficacy in patients with advanced gastric cancer.
Prospective and and retrospective multicenter observational study of HER2 status just before T-DXd administration and treatment efficacy in patients with advanced gastric cancer.
HGCSG 2303
| Japan |
Unresectable or advanced recurrent HER2-positive gastric cancer or cardioesophageal cancer.
| Gastroenterology |
Malignancy
NO
To elucidate the association between HER2 status and treatment outcome just before T-DXd administration to patients with advanced gastric cancer.
Efficacy
Response rate
Progression free survival, Disease control rate, Overall survival, Safety, HER2 Status
Observational
| 20 | years-old | <= |
| Not applicable |
Male and Female
1. Patients who have failed prior trastuzumab-based chemotherapy for unresectable advanced or recurrent gastric cancer.
2. Patients who have undergone (or will undergo) tissue collection (biopsy or surgery) and HER2 testing after completion of trastuzumab-containing chemotherapy.
3. Over 20 years of age.
4. Eastern Cooperative Oncology Group(ECOG) Performance Status(PS) 0-2.
5. Written informed consent.
1. Those with active multiple cancers.
2. Those who had drainage for fluid retention (pleural, ascites, pericardial fluid, etc.) within 2 weeks prior to enrollment.
3. Patients with pulmonary fibrosis or interstitial pneumonia.
4. Those with serious complications.
5. Those with active infectious diseases.
6. Those with active viral hepatitis.
7. Poorly controlled diabetes mellitus patients.
8. Those with serious psychiatric or central nervous system disorders.
9. Those with severely abnormal electrocardiogram or with clinically problematic cardiac condition.
10. Other individuals who are judged by the research director or co-researcher to be inappropriate as research subjects.
60
| 1st name | Yoshito |
| Middle name | |
| Last name | Komatsu |
Hokkaido University Hospital
Division of Cancer Center
060-8648
Kita14, Nishi5, Kita-Ku, Sapporo Hokkaido, Japan
0117161161
ykomatsu@med.hokudai.ac.jp
| 1st name | Koichi |
| Middle name | |
| Last name | Ishida |
Hokkaido University Hospital
Department of Gastroenterology and Hepatology
060-8648
Kita14, Nishi5, Kita-Ku, Sapporo Hokkaido, Japan
0117161161
ishida.koichi.e3@elms.hokudai.ac.jp
Hokkaido university hospital
Hokkaido university hospital, Hokkaido Gastrointestinal Cancer Study Group(HGCSG)
Other
Ethical Review Board for Life Science and Medical Research, Hokkaido University Hospital
Kita 14, Nishi 5, Kita-ku, Sapporo, Hokkaido
0117161161
crjimu@huhp.hokudai.ac.jp
NO
| 2024 | Year | 08 | Month | 02 | Day |
Unpublished
Enrolling by invitation
| 2024 | Year | 03 | Month | 25 | Day |
| 2024 | Year | 06 | Month | 07 | Day |
| 2024 | Year | 06 | Month | 07 | Day |
| 2025 | Year | 06 | Month | 30 | Day |
Research implementation period: Until March 31, 2026
| 2024 | Year | 08 | Month | 01 | Day |
| 2024 | Year | 08 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000062936